Boehringer Ingelheim has named Eisai’s Uday Bose as head of global marketing for its oncology business.
Taking up the role on August 1, Bose will lead marketing efforts for Boehringer’s fledgling activities in cancer, which has become an increasingly important area for the company since the launch of its first oncology product Giotrif (afatinib) last year.
Since then Boehringer has also filed its second cancer product nintedanib for approval in lung cancer.
Bose’s responsibilities include the long-term marketing plan for the cancer portfolio, as well as the development of global strategies for Boehringer’s cancer products and guiding the launch and marketing of individual drugs.
Bose is currently head of the oncology business unit for the EMEA region at Eisai – a position he has held since 2010. His past experience include senior marketing roles at GSK’s oncology business and product manager positions at Sanofi.